Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now?
Nektar Therapeutics (NKTR) is drawing attention after recent trading left the share price at US$57.06, with the stock down 4% on the day and weaker over the past month.
Nektar Therapeutics has seen momentum fade in recent weeks, with the share price return down 21.32% over the past month and 18.26% over 90 days. This comes even though the year-to-date share price return is still up 31.41%, the 3-year total shareholder return is very large, and the 5-year total shareholder return remains down 79%.
Scan beyond Nektar Therapeutics and compare this move with a curated group of beaten-up opportunities on the 16 high quality undiscovered gems.
For Nektar Therapeutics, a sharp pullback after a strong year-to-date gain raises a simple issue. Is the latest slide pointing to cracks in the business, or is it simply resetting sentiment before investors reassess valuation?
Most Popular Narrative: 60.5% Undervalued
On the most followed view, Nektar Therapeutics screens as materially cheaper than an estimated fair value of $144.40, with the narrative built around late stage trial progress and a long cash runway rather than near term profitability.
Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk, which supports earnings predictability and reduces financial leverage concerns.
See why 13 investors see Nektar Therapeutics as 60% undervalued.
Result: Fair Value of $144.40 (UNDERVALUED)
Still, Nektar Therapeutics remains heavily tied to rezpeg outcomes, and ongoing losses with no approved products could pressure that cash runway faster than bullish investors expect.
Find out about the key risks to this Nektar Therapeutics narrative.
Another View on Nektar Therapeutics Valuation
The popular narrative has Nektar Therapeutics looking 60.5% below a fair value of $144.40, yet the current market tag tells a different story. On a simple P/S basis, NKTR trades at 35.7x sales versus 4.8x for the wider US Pharmaceuticals group and 15.3x for closer peers.
That is more than double the peer average and over three times the sector, while the fair ratio sits at 11.2x. If the share price ever drifted closer to that fair ratio, the adjustment would come from a much lower multiple rather than a higher one, which sets up a very different kind of risk dial for investors to consider.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed takes like this can be useful, but your own judgment matters more than any single framework. Weigh both sides and then dig into the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Nektar Therapeutics?
If you only stop at Nektar Therapeutics, you risk missing other compelling setups that fit your preferences on quality, risk and income potential.
- Target potential mispricings by scanning a focused universe of companies that combine quality with attractive entry points through the 32 high quality undervalued stocks.
- Build a sturdier core by zeroing in on businesses with healthier finances and dependable fundamentals using the list of solid balance sheet and fundamentals (24 results).
- Strengthen your income stream by hunting for payout-focused opportunities that also offer robust profiles with the 8 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com